Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma

• Published in: Blood Vol. 121; no. 6; pp. 884 - 892
• Main Authors: Bergsagel, P. Leif, Mateos, María-Victoria, Gutierrez, Norma C., Rajkumar, S. Vincent, San Miguel, Jesús F.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 07.02.2013; American Society of Hematology
• Subjects: Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Boronic Acids - administration & dosage; Boronic Acids - therapeutic use; Bortezomib; Chromosome Aberrations; Clinical Trials and Observations; Dexamethasone - administration & dosage; Dexamethasone - therapeutic use; Humans; Lenalidomide; Lymphoid Neoplasia; Multiple Myeloma - drug therapy; Multiple Myeloma - genetics; Multiple Myeloma - pathology; Prognosis; Pyrazines - administration & dosage; Pyrazines - therapeutic use; Randomized Controlled Trials as Topic; Risk Factors; Survival Analysis; Thalidomide - administration & dosage; Thalidomide - analogs & derivatives; Thalidomide - therapeutic use; Treatment Outcome

Multiple myeloma (MM) is a heterogeneous disease with certain genetic features [eg, t(4;14), del17p] associated with worse outcome. The introduction of thalidomide, lenalidomide, and bortezomib has dramatically improved the outlook for patients with MM, but their relative benefit (or harm) for diffe...